I.1 hrs). ALD403 was well-tolerated with no serious related adverse events reported.

**Conclusion:** In this post hoc analysis, on the first full day (24 hours) after administration of a single IV infusion, reductions in both the proportion of patients experiencing a migraine and the number of migraine hours experienced on that day were greater relative to baseline for patients receiving ALD403 (optinezumab) compared to those receiving placebo. These observations suggest an early onset of migraine preventive efficacy, which may be related to IV administration, the unique pharmacokinetic and pharmacodynamic attributes of ALD403 (optinezumab), the specific mechanism of action, or some combination of these attributes.

**Disclosure of Interest**

**Neuromodulation for Headache**

**EP-01-020**

**Effect of cathodal transcranial direct current stimulation of the primary motor and sensory cortex on migraine**

Mohammad Radad Rahimi1,2, Javad Salebi Fadardi2,3, Imanola Bigele2,3, Mortaza Sani2,3, Mohammad Mahdi Ghasemi1 and Karim Nikkham1

1Ferdowsi University of Mashhad and Mashhad University of Medical Sciences, Herat, Afghanistan
2Psychology, Ferdowsi University
3Neurology
4Ear, nose, and throat, Mashhad University of Medical Sciences, Mashhad, Iran, Islamic Republic Of

**Objectives:** Transcranial direct current stimulation is a novel technological method that has been used in the scope of pain related diseases like migraine-as a prevalent and high burden disease extensively. The aim of the present study was to evaluate the effectiveness of cathodal transcranial direct current stimulation (c-tDCS) over the right primary motor (M1) and sensory (S1) areas of the cortex on decreasing the intensity, duration, and frequency of pain in migraineurs.

**Methods:** This study was based on a randomized, double-blind, and sham-controlled design, and it tested 15 seasons (every week three seasons; over 5 consecutive weeks) of c-tDCS (20 min/1000µA) on forty-five migraineurs (diagnosed according to the IHCD-II) into two experimental (nm = 15; ns = 15) and a control group (n = 15).

Image:

**Results:** The results of a series of one-way ANOVA, c-tDCS showed significant (p < 0.05) reductions in all hypothesized aspects of pain in both experimental groups compared to the control one.

**Conclusion:** Therefore, it seems that c-tDCS can be used as a technological method in the treatment of migraine both therapeutically and prophylactically.

**Disclosure of Interest**
None Declared

**Neuromodulation for Headache**

**EP-01-021**

**sTMS Blocks Cortical Spreading Depression by Suppressing Spontaneous Cortical Neuronal Firing and by Increasing the Threshold of Activation of the Occipital Cortex**

J. O. Lloyd1, M. N. Okine1, M. G. Jones2,3, G. Lambi1,4, S. B. McMahon5, A. P. Andreou1,5; Headache group, Wolfson CARD

1Headache Research-Wolfson CARD
2Neurorestoration Department-Wolfson CARD, King's College London
3Zenith Neurotech Ltd
4Headache Centre, Guy's and St Thomas' NHS Trust, London, United Kingdom

**Objectives:** Single-pulse transcranial magnetic stimulation (sTMS) is a non-invasive neuromodulation technique that has been shown to be a successful acute and preventative treatment for migraine patients with and without aura. In vivo, sTMS has been previously shown to block cortical spreading depression (CSD) and thalamic neuronal activity.